Several factors predispose individuals to NeuroHIV, including the direct neurotoxic effects of HIV-1, the inflammation it triggers in the brain (neuroinflammation), the potential neurotoxicity of ART drugs, and sociodemographic characteristics like age and the presence of co-occurring health conditions [5]
Here are the most important developments to watch in the coming year: 190 Obesity Drugs in the Pipeline IQVIAs 2026 analysis identified 190 obesity-related products currently in pharmaceutical development
The majority of peptide therapies are delivered through an IV or by subcutaneous injections, rather than by oral supplements
Starting at 0.25 mg weekly and titrated up to 2.4 mg, it provides: Potent glycemic control Clinically significant weight loss Metabolic and cardiovascular benefits It represents a well-established and effective therapeutic option for patients seeking long-term metabolic health improvement.
Weight loss remains one of the most effective ways to improve insulin resistance
P.Arango-DavilaC.Gallego-GmezJ